Current and historical daily PE Ratio for BioLine Rx Ltd (
XTAE:BLRX
) from 2007 to May 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. BioLine Rx stock (XTAE:BLRX) PE ratio as of May 01 2024 is 0.
More Details
BioLine Rx Ltd (XTAE:BLRX) PE Ratio (TTM) Chart
BioLine Rx Ltd (XTAE:BLRX) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| BioLine Rx PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-01 | At Loss | 2024-02-19 | At Loss |
| 2024-04-30 | At Loss | 2024-02-18 | At Loss |
| 2024-04-25 | At Loss | 2024-02-15 | At Loss |
| 2024-04-24 | At Loss | 2024-02-14 | At Loss |
| 2024-04-21 | At Loss | 2024-02-13 | At Loss |
| 2024-04-18 | At Loss | 2024-02-12 | At Loss |
| 2024-04-17 | At Loss | 2024-02-11 | At Loss |
| 2024-04-16 | At Loss | 2024-02-08 | At Loss |
| 2024-04-15 | At Loss | 2024-02-07 | At Loss |
| 2024-04-14 | At Loss | 2024-02-06 | At Loss |
| 2024-04-11 | At Loss | 2024-02-05 | At Loss |
| 2024-04-10 | At Loss | 2024-02-04 | At Loss |
| 2024-04-09 | At Loss | 2024-02-01 | At Loss |
| 2024-04-08 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-28 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-31 | At Loss | 2024-01-24 | At Loss |
| 2024-03-28 | At Loss | 2024-01-23 | At Loss |
| 2024-03-27 | At Loss | 2024-01-22 | At Loss |
| 2024-03-26 | At Loss | 2024-01-21 | At Loss |
| 2024-03-25 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-15 | At Loss |
| 2024-03-18 | At Loss | 2024-01-14 | At Loss |
| 2024-03-17 | At Loss | 2024-01-11 | At Loss |
| 2024-03-14 | At Loss | 2024-01-10 | At Loss |
| 2024-03-13 | At Loss | 2024-01-09 | At Loss |
| 2024-03-12 | At Loss | 2024-01-08 | At Loss |
| 2024-03-11 | At Loss | 2024-01-07 | At Loss |
| 2024-03-10 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2024-01-01 | At Loss |
| 2024-03-05 | At Loss | 2023-12-31 | At Loss |
| 2024-03-04 | At Loss | 2023-12-28 | At Loss |
| 2024-03-03 | At Loss | 2023-12-27 | At Loss |
| 2024-02-29 | At Loss | 2023-12-26 | At Loss |
| 2024-02-28 | At Loss | 2023-12-25 | At Loss |
| 2024-02-26 | At Loss | 2023-12-24 | At Loss |
| 2024-02-25 | At Loss | 2023-12-21 | At Loss |
| 2024-02-22 | At Loss | 2023-12-20 | At Loss |
| 2024-02-21 | At Loss | 2023-12-19 | At Loss |
| 2024-02-20 | At Loss | 2023-12-18 | At Loss |
BioLine Rx Ltd (XTAE:BLRX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
BioLine Rx Ltd
ISIN : IL0011015182
Compare
Compare
Traded in other countries / regions
BLRX.IsraelBLRX.USAYP2A.Germany IPO Date
2007-02-11Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers